达拉图穆马
Carfilzomib公司
医学
养生
多发性骨髓瘤
地塞米松
肿瘤科
耐火材料(行星科学)
内科学
硼替佐米
天体生物学
物理
作者
Shambavi Richard,Sundar Jagannath,Hearn Jay Cho,Samir Parekh,Deepu Madduri,Joshua Richter,Ajai Chari
标识
DOI:10.1080/17474086.2021.1858790
摘要
Introduction: Novel, effective regimens are needed in patients with relapsed and refractory myeloma (RRMM) who inevitably relapse after PI and IMID containing treatment. Areas covered: Pre-clinical data, early clinical and pivotal trials relevant to the development of the two backbone drugs of carfilzomib and daratumumab, and the two important recent trials, EQUULEUS and CANDOR leading to the FDA approval of the combination regimen of daratumumab, carfilzomib, and dexamethasone (DKd) for RRMM are detailed in this review. Expert opinion: EQUULEUS and CANDOR have established the efficacy of the DKd regimen in the landscape of bortezomib and lenalidomide refractory patients. The split dosing schedule of the first dose of daratumumab was approved by the FDA based on EQUULEUS, significantly improving patient convenience. Subcutaneous daratumumab is being evaluated in this combination to further improve tolerance and convenience. Further studies are needed to evaluate and optimally sequence the many effective and potent drugs available in RRMM.
科研通智能强力驱动
Strongly Powered by AbleSci AI